-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing Arcellx (NASDAQ:ACLX) & Achilles Therapeutics (NASDAQ:ACHL)
Reviewing Arcellx (NASDAQ:ACLX) & Achilles Therapeutics (NASDAQ:ACHL)
Arcellx (NASDAQ:ACLX – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
Insider and Institutional Ownership
91.8% of Arcellx shares are held by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Get Arcellx alerts:Analyst Recommendations
This is a breakdown of current recommendations and price targets for Arcellx and Achilles Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Arcellx | 0 | 0 | 8 | 0 | 3.00 |
Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
Profitability
This table compares Arcellx and Achilles Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Arcellx | N/A | -68.99% | -42.26% |
Achilles Therapeutics | N/A | -26.40% | -23.89% |
Earnings & Valuation
This table compares Arcellx and Achilles Therapeutics' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.71 |
Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.48 |
Arcellx is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Achilles Therapeutics beats Arcellx on 7 of the 10 factors compared between the two stocks.
About Arcellx
(Get Rating)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
About Achilles Therapeutics
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
Arcellx (NASDAQ:ACLX – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
纳斯达克:ACLX-GET评级)和阿喀琉斯治疗公司(纳斯达克:ACHL-GET评级)都是小盘医疗公司,但哪只股票更优越?我们将根据这两家公司的股息、估值、机构所有权、分析师建议、盈利能力、风险和收益的实力进行比较。
Insider and Institutional Ownership
内部人与机构持股
91.8% of Arcellx shares are held by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Arcellx 91.8%的股份由机构投资者持有。相比之下,阿喀琉斯治疗公司69.7%的股份由机构投资者持有。阿喀琉斯治疗公司5.4%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一只股票的长期表现将好于大盘。
Analyst Recommendations
分析师建议
This is a breakdown of current recommendations and price targets for Arcellx and Achilles Therapeutics, as provided by MarketBeat.
这是MarketBeat提供的Arcell和Achilles治疗公司目前的建议和价格目标的细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Arcellx | 0 | 0 | 8 | 0 | 3.00 |
Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
阿尔塞克斯 | 0 | 0 | 8 | 0 | 3.00 |
阿喀琉斯治疗学 | 0 | 1 | 2 | 0 | 2.67 |
Profitability
盈利能力
This table compares Arcellx and Achilles Therapeutics' net margins, return on equity and return on assets.
此表比较了Arcell和Achilles Treeutics的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Arcellx | N/A | -68.99% | -42.26% |
Achilles Therapeutics | N/A | -26.40% | -23.89% |
净利润率 | 股本回报率 | 资产回报率 | |
阿尔塞克斯 | 不适用 | -68.99% | -42.26% |
阿喀琉斯治疗学 | 不适用 | -26.40% | -23.89% |
Earnings & Valuation
收益与估值
This table compares Arcellx and Achilles Therapeutics' revenue, earnings per share and valuation.
此表比较了Arcell和Achilles Treeutics的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.71 |
Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.48 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
阿尔塞克斯 | 不适用 | 不适用 | -6,497万元 | ($44.41) | -0.71 |
阿喀琉斯治疗学 | 不适用 | 不适用 | -6,110万美元 | ($1.66) | -0.48 |
Arcellx is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arcellx的市盈率低于阿喀琉斯治疗公司,这表明它目前是两只股票中更负担得起的一只。
Summary
摘要
Achilles Therapeutics beats Arcellx on 7 of the 10 factors compared between the two stocks.
在两只股票之间的10个因素中,阿喀琉斯治疗公司有7个因素超过了Arcell。
About Arcellx
关于Arcellx
(Get Rating)
(获取评级)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Arcell,Inc.是一家临床阶段的生物技术公司,致力于为癌症和其他不治之症患者开发各种免疫疗法。该公司主要的ddCAR候选产品是CART-ddBCMA,这是一种治疗复发或难治性(r/r)多发性骨髓瘤(MM)患者的第一阶段临床试验。该公司还在开发ACLX-001,这是一种由ARC-T细胞和针对BCMA的双价SPARX蛋白组成的免疫治疗组合,用于治疗r/r MM;ACLX-002和ACLX-003用于治疗r/r急性髓系白血病(AML)和骨髓增生异常综合征(MDS);以及其他AML/MDS候选产品,以及实体肿瘤计划。该公司前身为Encarta治疗公司,并于2016年1月更名为Arcell,Inc.。Arcell,Inc.成立于2014年,总部位于马里兰州盖瑟斯堡。
About Achilles Therapeutics
阿喀琉斯疗法公司简介
(Get Rating)
(获取评级)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
阿喀琉斯治疗公司是一家临床阶段免疫肿瘤学生物制药公司,开发用于治疗各种实体肿瘤的精密T细胞疗法。该公司的主要候选产品包括用于治疗晚期非小细胞肺癌的处于I/IIa阶段临床试验的ChIron和用于治疗转移性或复发黑色素瘤的处于I/IIa阶段临床试验的候选产品Thetis。它还在开发用于治疗头颈部鳞状细胞癌、肾细胞癌、三阴性乳腺癌和膀胱癌的产品。该公司前身为Achilles TX Limited,2021年2月更名为Achilles Treateutics Plc。该公司成立于2016年,总部设在英国伦敦。
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
接受Arcell Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收Arcell和相关公司的最新新闻和分析师评级的每日简明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧